Evidence map›Paper›PMID 38268409›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2024

Long-term outcome of kidney function in patients with ANCA-associated vasculitis.

Beatriz Sachez-Alamo, Laura Moi, Ingeborg Bajema, Annelies Berden, Oliver Flossmann, Zdenka Hruskova, David Jayne, Maria Wester-Trejo, Carin Wallquist, Kerstin Westman

Erratum issuedAbstract read
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Understanding the burden of ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2026
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Beatriz Sachez-AlamoDepartment of Clinical Sciences Lund, Division of Nephrology, Lund University, Sweden.
Laura MoiDivision of Immunology and Allergy Department of Medicine, University Hospital of Lausanne, Lausanne University, Lausanne, Switzerland.
Ingeborg BajemaDepartment of Pathology, Groningen, The Netherlands.
Annelies BerdenDepartment of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, The Netherlands.
Oliver FlossmannDepartment of Nephrology, Royal Berkshire Hospital, Reading, UK.
Zdenka HruskovaDepartment of Nephrology, General Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic.
David JayneDepartment of Medicine, University of Cambridge, Cambridge, UK.
Maria Wester-TrejoDepartment of Pathology, Leiden University Medical Centre, Leiden, The Netherlands.
Carin WallquistDepartment of Nephrology, Skane Univ. Hospital Malmö, Malmö, Sweden.
Kerstin WestmanDepartment of Clinical Sciences Lund, Division of Nephrology, Lund University, Lund, Sweden.

Funding

European Renal AssociationNjurfondenRegion Skane REG-SKANE_924921Swedish Kidney FundVasculitis Foundation
6 · The paper itself

Abstract

backgroundKidney involvement is common in anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) and the prognosis is determined by the severity of kidney damage. This study focused on long-term kidney outcomes, defining possible risk factors and comparing the performance of three different histological classifications to predict outcomes for patients with AAV.

methodsThe dataset included 848 patients with newly diagnosed AAV who participated in seven randomized controlled trials (RCTs) (1995-2012). Follow-up information was obtained from questionnaires sent to the principal investigators of the original RCTs.

resultsThe cumulative incidence of end-stage kidney disease (ESKD) at 5 and 10 years was 17% and 22%, respectively. Patients who developed ESKD had reduced patient survival compared with those with preserved kidney function (hazard ratio 2.8, P < .001). Comparing patients with AAV and kidney involvement with a matched general population, patients with AAV had poor survival outcomes, even in early stages of chronic kidney disease. The main cause of death was infection followed by cardiovascular disease in patients developing ESKD and malignancy in those who did not. Some 34% of patients with initial need for dialysis recovered kidney function after treatment. Thirty-five out of 175 in need of kidney replacement therapy (KRT) during follow-up received a kidney transplant with good outcome; there was 86% patient survival at 10 years.In the subcohort of 214 patients with available kidney biopsies, three scoring systems were tested: the Berden classification, the Renal Risk Score and the Mayo Clinic Score. The scores highlighted the importance of normal glomeruli and severe glomerulosclerosis on kidney survival (P < .001 and P = .001, respectively). The Renal Risk Score demonstrated a moderate prediction of kidney survival (area under the curve 0.79; standard error 0.03, 95% confidence interval 0.71-0.83).

conclusionsEarly diagnosis of AAV is extremely important. Even milder forms of kidney involvement have an impact on the prognosis. Patients in need of KRT had the lowest survival rates, but kidney transplantation has shown favorable outcomes for eligible AAV patients. The three histologic scoring systems were all identified as independent prognostic factors for kidney outcome.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisKidney Failure, ChronicAdultAgedFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidney Function TestsMaleMiddle AgedPrognosisRisk FactorsSurvival RateANCA-associated vasculitisend-stage kidney diseasekidney histology scoresprognosistransplantation

Identifiers

PMID38268409
PMCPMC11361807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.